Work

A phase I study of the anti-insulin like growth factor type 1 receptor (IGF-1R) antibody dalotuzumab in pediatric patients with advanced solid tumors.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.10026

Authors: Didier Frappaz, Lisa M. McGregor, Andrew DJ Pearson, Lia Gore, Steven G. DuBois, Isabelle Aerts, Robert Iannone, Ryan Geschwindt, Arne Van Schanke, Ruixue Wang, Birgit Geoerger

Institutions: Institut d’Hématologie et d’Oncologie Pédiatrique, St. Jude Children's Research Hospital, Institute of Cancer Research, Royal Marsden Hospital, University of Colorado Denver, University of California, San Francisco, Institut Curie, Merck & Co., Inc., Rahway, NJ, USA (United States), Institut Gustave Roussy

Language: English

Topic: Growth Hormone and Insulin-like Growth Factors

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2527266916

Cites:

Cited by: 1

Related to: 10